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SUMMARY

Obesity is a multi-systemic disorder of energy balance. Despite intense investigation, the determinants of
energy homeostasis remain incompletely understood, and efficacious treatments against obesity and its
complications are lacking. Here, we demonstrate that conferred arginine iminohydrolysis by the bacterial
virulence factor and arginine deiminase, arcA, promotes mammalian energy expenditure and insulin sensitivity and reverses dyslipidemia, hepatic steatosis, and inflammation in obese mice. Extending this, pharmacological arginine catabolism via pegylated arginine deiminase (ADI-PEG 20) recapitulates these metabolic
effects in dietary and genetically obese models. These effects require hepatic and whole-body expression
of the autophagy complex protein BECN1 and hepatocyte-specific FGF21 secretion. Single-cell ATAC
sequencing further reveals BECN1-dependent hepatocyte chromatin accessibility changes in response to
ADI-PEG 20. The data thus reveal an unexpected therapeutic utility for arginine catabolism in modulating energy metabolism by activating systemic autophagy, which is now exploitable through readily available pharmacotherapy.

INTRODUCTION
Obesity is a disorder of energy balance afflicting an estimated 1
in 5 individuals worldwide.1 It is associated with multiple morbidities, including metabolic syndrome, cardiovascular death, type
2 diabetes mellitus, and non-alcoholic steatohepatitis.2 Yet,
despite decades of investigation into the determinants of energy
homeostasis, the incidence of overweight, obesity, and their
complications continue to rise worldwide. Currently available
therapies that modulate energy homeostasis as a root cause to
these complex disorders are limited in number, efficacy, and
mechanistic action.
Intermittent fasting and caloric restriction (IF and CR) are
effective therapies against obesity and its complications,
including non-alcoholic fatty liver disease (NAFLD), dyslipidemia,
and insulin resistance, in mice and in humans.3–8 However, intensive lifestyle modifications are rarely sustainable in real-world
settings.9 We previously found that the hepatocyte response to
glucose deprivation is sufficient to mimic several key therapeutic
effects of generalized IF and CR on hepatic steatosis, hepatic
inflammation, and insulin resistance,10–19 in part by inducing hepatocyte autophagic flux and secretion of the anti-diabetic hep-

atokine, FGF21.20 We thus set out here to leverage this pathway
against metabolic disease. Clinically, this approach is of particular interest, because hepatocyte glucose transport and its
downstream pathways are amenable to pharmacological
therapy.
We previously identified the arginine ureahydrolase, arginase
2 (ARG2), as a hepatocyte glucose withdrawal-induced factor.
Induction of ARG2 is sufficient to exert part of the therapeutic
metabolic sequelae of caloric restriction.16 Subsequent data
further demonstrated that arginase 1 and 2 polymorphisms
determine circulating arginine levels in arginine-supplemented
and unsupplemented dietary contexts. Together, the data initiated the hypothesis that augmenting arginine catabolism can
modulate host arginine status—and thereby therapeutically
direct energy metabolism.
Whereas mammalian ARG2 is a low-affinity (Km 2mM), moderate-capacity arginine ureahydrolase,21 we turned to the therapeutic potential of a naturally occurring, high-affinity arginine
iminohydrolase, arcA, as a potentially more efficacious means
by which to modify host arginine status. arcA is a bacterial virulence factor that is evolutionarily primed for this duty, because its
high binding affinity for ARG2 (Km = 34.5 mM) permits bacterial

Cell Reports Medicine 3, 100498, January 18, 2022 ª 2021 The Author(s). 1
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

ll
OPEN ACCESS

Article

Figure 1. Hepatic AAV8-mediated arcA increases thermogenesis and insulin sensitivity in db/db mice
(A) Schematic of experimental design used to test the role of AAV8-mediated mouse codon optimized arcA overexpression in db/db mice.
(B and C) Body weight (B) and body fat and lean mass (C) percentage of composition of AAV8-eGFP or AAV8-arcA-injected db/db mice (n = 8 mice per group).
(D) Whole-body oxygen consumption (VO2), carbon dioxide (VCO2), and energy expenditure during light and dark cycle (shaded area) in AAV8-injected db/db
mice.
(E) Quantified VO2, VCO2, and energy expenditure during light and dark cycle.
(F) Body weight to energy expenditure regression test during light and dark cycle.
(G) Serum glucose in AAV8-eGFP and AAV8-arcA-treated db/db mice.
(H and I) Intraperitoneal tolerance tests for insulin (ITT, H) and for glucose (GTT, I).

(legend continued on next page)
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niche establishment by competing arginine away from host inflammatory nitric oxide synthases and toward bacterial ATP production.22 The favorable enzymatic properties of arcA and the
ready availability of a pharmacotherapy that mimics these properties led us to examine efficacy and mechanisms of therapeutic
arginine catabolism against obesity and its complications.
Here, we demonstrate that hepatocyte and systemic arginine
status is therapeutically modifiable, particularly through the bacterial arginine deiminase, arcA. Hepatocyte-directed arcA expression increased basal caloric expenditure and improved glucose
and insulin tolerance in genetically diabetic mice. We then provide
evidence corroborating the insulin-sensitizing and thermic effects
of a arginine deiminase-based pharmacological agent, ADI-PEG
20. Mechanistically, we show enhanced arginine catabolism exerts its therapeutic effects on host metabolism by activating systemic autophagic flux and hepatocyte-specific FGF21 secretion.
We conclude that hepatocyte and systemic arginine catabolism
play a canonical role in dictating peripheral energy and insulin homeostasis, which is pharmacologically modifiable using readily
available agents.
RESULTS
Ectopic expression of the arginine deiminase, arcA,
induces thermogenesis and insulin sensitivity
The mammalian arginine ureahydrolases, arginase 1 and arginase 2 (ARG1 and ARG2), mediate arginine hydrolysis to ornithine and urea with low substrate affinity. We reported that
fasting induces hepatocyte arginase 2 (Arg2) expression, and
that Arg2 upregulation in the absence of caloric restriction is sufficient to induce peripheral thermogenesis and insulin sensitization in genetic and diet-induced obese animals. This suggested
that either or both arginine catabolism per se and ARG2 scaffolding and signaling mediate these effects. To test the hypothesis that hepatocyte arginine catabolism enhances hepatic and
peripheral energy metabolism apart from ARG2 upregulation,
and apart from ARG2 products ornithine and urea, we expressed
arcA in hepatocytes. arcA encodes a high-affinity arginine deiminase23 that differs from the arginases in its enzymatic products,
citrulline and ammonia.22 We delivered arcA or eGFP (an ectopic
expression control vector) via tail-vein injection of AAV8 encoding arcA or eGFP under hepatocyte-specific thyroxine binding
globulin promoter control in 5-week-old db/db mice. Five weeks
following gene delivery, we verified arcA expression (Figure S1A)
and subjected all mice to a battery of metabolic assays and tissue collection (Figure 1A). Hepatocyte-directed arcA increased
body mass-by-time interaction with modest but significant increases in fat mass percentage and lower lean mass percentage
(Figures 1B and 1C), as quantified by echoMRI analysis. Nonetheless, hepatocyte arcA increased VO2, VCO2 and caloric
expenditure throughout both dark and light cycles (Figures 1D
and 1E) without altering respiration exchange rate (RER), total
locomotion (Figures S1B and S1C), or food consumption (Fig-
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ure S1D). Analysis of covariance (ANCOVA) further confirmed
significantly different heat versus body-weight regression relationships (Figure 1F). arcA reduced fasting serum glucose and
improved glucose and insulin tolerance testing (Figures 1G,
1H, and 1I). In contrast, fasting serum low-density lipoprotein
cholesterol (LDL-C) and NEFA were significantly decreased,
whereas fasting triglycerides (TGs) and total cholesterol (TC)
were trended toward and significantly elevated in arcA-expressing diabetic mice, respectively (Figures 1J–1M).
Hepatic metabolic analysis revealed that serum alanine
aminotransferase and aspartate aminotransferases (ALT and
AST), markers of hepatocellular lysis and enzymatic excursion,
were lower in arcA-expressing mice, whereas hepatocyte synthetic function, as quantified by serum albumin, was unchanged
in ADI-expressing versus GFP-expressing db/db mice (Figures
2A–2C). This hepatoprotective effect of ADI expression correlated with reduced percentage steatotic area on histologic
quantification (Figure 2D) and reduced intrahepatic TGs, TC,
and non-esterified fatty acids (NEFA, Figures 2E–2G), but
without changes in liver mass, or liver-weight-to-body-weight
ratio (Figures S1E and S1F). Targeted hepatic metabolomics revealed significantly lower intrahepatic ornithine, citrulline, asparagine, and alanine, to suggest an arginine shunt away from urea
cycle flux (Figure 2H). Liver transcriptomic analysis revealed
clear separation in gene expression profiling secondary to arcA
expression when compared with GFP-expressing controls (Figures 2I, 2J, and 2K). Although arcA expression increased fatty
acid import and decreased fatty acid export gene expression
of Cd36 and Mttp, respectively, via quantitative real-time PCR
(Figure S1G), pathway analysis revealed significant upregulation
in multiple metabolic processes upon arcA overexpression,
including organic and fatty acid metabolism, arachidonic acid
metabolism,14 and fatty acid oxidation (Figures 2L, left panel,
and S1H). Concomitantly, we observed suppression in pro-inflammatory pathways, including adhesion, locomotion, cell
migration, immune regulation, and immune effector responses
(Figure 2L, right panel). Transcriptomic suggestions of suppressed inflammation were confirmed by quantitative real-time
PCR, demonstrating decreased hepatic expression of Il-1b, Il6, Tnf-a, Ccl2, and Cxcl9 (Figure S1I). Markers of macrophage
infiltration, Cd68 and Mmp2, along with markers of fibrosis
development, Col1a1 and Timp1, are also suppressed by arcA
overexpression in the liver (Figures S1J and S1K). Consistent
with the reduction in inflammatory response, hepatocyte-specific overexpression of arcA also led to significant increases in
expression of gene encoding urea cycle enzymes like Ass1,
Otc, and Cps1 (Figures S1L), and a significant decrease in Glul
expression (Figures S1M). These findings mirrored the increased
energy expenditure and anti-inflammatory phenotypes observed
previously in Arg2-overexpressing liver.16 Moreover, these hepatic metabolic and inflammatory improvements associated
with enhanced arcA-induced LC3B-II and FGF21 protein accumulation in liver and serum—each serving as biomarkers of

(J–M) Serum non-esterified fatty acid (FFA, J), low-density lipoprotein cholesterol (LDL-C, K), triglycerides (TGs, L), and cholesterol (TC, M) in AAV8-eGFP and
AAV8-arcA-treated db/db mice.
Data represented in mean ± SEM. Each data point represents an individual animal. Exact p values are shown. Statistical significance was determined using twoway ANOVA in (B), (D), (H), and (I). Unpaired two-tailed Student’s t test was used in (C), (E), (G), and (J)–(M).
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hepatocyte fasting- and stress-response activation (Figures 2M–
2O).20,24 Cellular alterations in fasting signaling correlated with
enhanced cellular respiration, as quantified by Seahorse respirometry upon ADI overexpression in isolated mouse hepatocyte
cell line, AML12 (Figure 2P). Indeed, ADI expression significantly
induced time-by-treatment analysis of overall respiration, as well
as non-mitochondrial oxygen consumption and spare respiratory capacity, whereas we observed trends toward increased
basal and maximal capacity that did not reach statistical significance (Figure 2Q).
Pharmacological arginine catabolism induces
thermogenesis and insulin tolerance in genetically
diabetic mice
Hepatocyte-specific arcA expression ameliorated insulin resistance, glucose intolerance, and dyslipidemia in genetically
diabetic mice. ADI-PEG 20 is a stabilized, pegylated arginine deiminase conjugate that has been used against various cancers,
including hepatocellular carcinoma.25,26 We tested the hypothesis
that systemically administered arginine catabolism recapitulates
the metabolic effects of hepatocyte-directed arcA/ADI expression. To that end, we treated db/db diabetic mice with vehicle or
ADI-PEG 20 (5 IU/week intraperitoneally) for 5 weeks prior to metabolic testing and tissue analysis (Figure 3A). In contrast with hepatocyte arcA, ADI-PEG 20 attenuated weight gain (Figure 3B),
reduced endpoint fat mass percentage and increased lean mass
percentage (Figure 3C) relative to vehicle-treated db/db mice.
No changes were observed in ghrelin and leptin gene expression
and protein abundance (Figures S2A and S2B). Total daily food
consumption was significantly reduced with ADI-PEG 20 treatment (Figure S2C). However, temporal alignment of food intake
and body weight indicates rapid, statistically significant weight
loss several weeks prior to detection of changes in food consumption (Figure S2D). Together, the data suggested that mechanisms
apart from food intake are more likely to drive at least the acute
therapeutic effects of ADI-PEG 20 on body mass (Figures S2A–
S2D). These favorable changes in body weight and composition
were observed alongside light and dark cycle increases in VO2,
VCO2, and caloric expenditure (Figure 3D), in the absence of

changes in respiratory exchange ratio or locomotion (Figures
S2E and S2F). In light of observed body-weight-attenuating effects
of ADI-PEG 20, we performed linear regression analyses and analysis of covariance comparing heat:body weight relationships in
vehicle- and drug-treated animals. This confirmed significant differences in heat:weight regression curves (Figure 3E). Dissected
liver mass was lower, whereas no difference in liver mass: bodyweight ratio was observed. However, we observed a decrease in
WAT mass and WAT mass:body-weight ratio, and increased
iBAT mass:body-weight ratio in ADI-PEG 20-treated mice (Figures
S2G and S2H). This associated with ADI-PEG 20-induced cellular
oxidative respiration, as quantified by Seahorse respirometry in
murine hepatocyte cell line AML12 treated with 0.5 mg/mL ADIPEG 20 (72 h) versus vehicle (Figure 3F). Upon examining the parameters of oxidative respiration, ADI-PEG 20 treatment increased
basal oxygen consumption rate (OCR), maximal respiration, spare
respiratory capacity, and ATP-coupled respiration (Figure 3G).
Concordant with hepatocyte arcA effects, ADI-PEG 20 reduced
fasting glucose and glucose and insulin tolerance (Figures 3H–
3J) and fasting serum TGs, TC, NEFA, and LDL-C in ADI-PEG
20-treated mice relative to vehicle-treated mice (Figure 3K).
Hepatic metabolic characterization revealed lower serum ALT
and albumin (Figure 3L), with a trend toward improved intrahepatic TGs (22%, p = 0.0656), and significantly lower intrahepatic
cholesterol and NEFA after ADI-PEG 20 treatment (Figure 3M).
Interestingly, in contrast to arcA overexpression, we observed
increased Il-1b, Il-6, Tnf-a, Ccl2, and Cxcl9 (Figure S2I) along
with Cd68, but not Mmp2 (Figure S2J). However, no changes
were observed in fibrotic gene expression of Col1a1 and Timp1
(Figure S2K). To assess gene expression related to hepatic
ammonia production and scavenging, we measured the expression of urea cycle genes and glutamine synthetase (Glul). We
observed significant decrease in urea cycle gene expression
including Ass1, Slc25a15, Otc, and Cps1 (Figure S2L), and we
observed an increase in Glul expression (Figure S2M). Nevertheless, biochemical improvements were corroborated by percentage of steatotic area, which was significantly reduced in ADI-PEG
20-treated mice without evidence of cellular inflammatory infiltrate in treated or untreated liver (Figure 3N). Intrahepatic Fgf21

Figure 2. Hepatic AAV8-mediated arcA attenuates hepatic steatosis and inflammation in db/db mice
(A–C) Serum ALT (A), AST (B), and albumin (C) contents.
(D) Liver sections stained with hematoxylin and eosin (H&E) with steatotic area (e.g., aparenchymal space) quantified (right). Scale bars, 100 mm.
(E–G) Triglyceride (E), cholesterol (F), and non-esterified fatty acid (G) contents in the livers of AAV8-eGFP and AAV8-arcA mice.
(H) Targeted metabolomic analysis of serum amino acids and urea cycle intermediaries from db/db AAV8-eGFP and AAV8-arcA mice.
(I) Principal component analysis (PCA) plot of bulk liver RNA-seq samples from AAV8-eGFP and AAAV8-arcA-injected db/db mice. The first two principal
components (PCs) are plotted. Variance proportions are shown along each component axis. The plot model 56% of the total data variance.
(J) Volcano plot of the distribution of all differentially expressed genes between AAV8-eGFP and AAV8-arcA-injected db/db mice, mapping the 28 upregulated
genes (red), 255 downregulated genes (blue), and non-significant genes (gray). Black vertical lines highlight log fold changes (FC) of 2 and 2, while the black
horizontal line represents a padj of 0.05.
(K) Heatmap showing all significantly expressed genes in the livers of AAV8-arcA-injected db/db mice.
(L) Differentially up- (left) and downregulated (right) genes enriched and identified by Gene Ontology enrichment analysis of biological processes between the
livers of AAV8-eGFP and AAV8-arcA-injected db/db mice.
(M) Western blot analysis of FGF21 and LC3B in liver samples from db/db AAV8-eGFP and AAV8-arcA mice. b-actin was used as a loading control.
(N) Western blot quantifications of LC3B (left) and FGF21 (right) (n = 8 mice per group).
(O) Serum FGF21 contents.
(P and Q) From left to right, mitochondrial respiration (P), non-mitochondrial oxygen consumption, spare respiration capacity, basal respiration, and maximal
respiration (Q) in vitro AML12 treated with Ad-eGFP (n = 4) or Ad-arcA (n = 5).
Data represented in mean ± SEM. Each data point represents an individual animal. Exact p values are shown. Statistical significance was determined using twoway ANOVA in (P). Statistical significance was determined using unpaired two-tailed Student’s t test in (A)–(G), (N), (O), and (Q).
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mRNA (Figure S2N) and FGF21 protein, LC3BII, and circulating
FGF21 were greater in drug-treated mice, whereas hepatic p62/
SQSTM1 was unchanged (Figures 3O, 3P, and 3Q). Because
p62/SQSTM1 is also transcriptionally upregulated in response
to inflammation, oxidative, and other cellular stressors,27,28 we
quantified hepatic p62/Sqstm1 mRNA. This revealed a significant
p62/Sqstm1 mRNA downregulation in ADI-PEG 20-treated
mouse liver (Figure S2O). Interrogation of hepatic mTORC
signaling in ADI-PEG 20-treated mice revealed significantly lower
phosphorylated p70S6K (threonine 389) and trends toward
reduced mTOR (serine 2448) phosphorylation. However, suppression of this arm of the pathway was associated with unaltered
ULK1 (serine 757) phosphorylation and with increased 4E-BP1
(threonine 36/47) (Figures S2P and S2Q). We observed enhanced
hepatocyte fasting-like and fatty acid oxidation-associated gene
expression via Fgf21 and Ucp1, increased fat oxidation gene
expression in Cpt1b, Ucp2, and Ucp3, and reduced hepatic gluconeogenic gene expression of Pck1, G6pc, and Fbp1 (Figures
S2N, S2R, and S2S),13 without changes in lipid transporters
Cd36 or Mttp or cell stress markers Grp78 or Atf4/Chop (Figures
S2T and S2U). Overall, ADI-PEG 20 reduced histologic and
biochemical hepatic steatosis in contexts of suppressed hepatic
fatty acid oxidation and gluconeogenic gene expression.
Hepatocyte FGF21 links systemic arginine catabolism to
the thermic and glucose homeostatic effects of ADIPEG 20 in a western-diet-fed model of metabolic
disease
Our data in genetically obese models previously16 and herein
indicate a protective effect of arginine hydrolysis in the progression of diabetes in a genetically predisposed model. We showed
the downstream signaling effectors of GLUT blockade, induce
FGF21 secretion.13 To more completely define and provide
mechanistic insights into the action of ADI-PEG 20, we relied
on a western diet (WD)-fed model of obesity to examine (1) the
extent to which arginine catabolic effects are generalizable

across obese models, (2) the degree to which ADI-PEG 20 can
reverse, as opposed to attenuate, progression of the deleterious
effects of obesity, and (3) the interaction between ADI-induced
hepatic FGF21 secretion and its therapeutic effects. We therefore placed wild-type (WT, e.g., Fgf21fl/fl genotype) male mice
and their hepatocyte-specific FGF21-deficient littermates
(FGF21 LKO, e.g., Fgf21fl/fl 3 albumin-Cre+) on a 12-week WD
(Figure 4A). Thereafter, mice were treated with ADI-PEG 20 (5
IU/week i.p.) for 4 weeks while continuously on diet for a total
of 16 weeks. In both WT and FGF21 LKO mice, ADI-PEG 20
reversed WD-induced weight gain (Figures 4B–4D) without
altering food consumption (Figure S3A). EchoMRI-based body
composition analysis demonstrated decreased fat accumulation
and concomitantly increased lean mass:total mass ratio in both
WD-fed WT and FGF21 LKO mice (Figure 4E). ADI-PEG 20
trended to increased O2-CO2 exchange and caloric expenditure
(Figure 4F) in the absence of changes to locomotion in WD-fed
WT mice (Figures S4B and S4C), and these effects were abrogated in FGF21 LKO mice, as quantified by linear analysis of
body heat:body weight regression curves (Figure 4G). In
contrast, fasting serum insulin levels and glucose tolerance
were improved in WD-fed WT and FGF21 LKO groups (Figures
4H and 4I). Interestingly, however, ADI-PEG 20 improved insulin
tolerance modestly, and yet this improvement was significantly
reversed in ADI-PEG 20-treated FGF21 LKO mice (Figure 4J).
Moreover, ADI-PEG 20 decreased fasting serum TGs, TC, and
NEFA in WD-fed WT mice. However, only the anti-dyslipidemic
effect on TGs, but not on TC, LDL-C, and NEFA, was reversed
in FGF21-deficient mice (Figures 4K–4N).
Hepatic analysis in this diet-induced obese model revealed
that ADI-PEG 20 did not alter liver weight:body mass ratios (Figures S3D and S3E), serum transaminases, or albumin in any
group (Figures 4O, 4P, and 4Q). ADI-PEG 20 reduced the percentage steatotic area histologically (Figure 4R), and this was
FGF21 dependent. Biochemical analysis of hepatic lipids
confirmed reduction of intrahepatic TGs, cholesterol, and

Figure 3. ADI-PEG 20 treatment improves whole-body metabolism and insulin sensitivity
Five-week-old male db/db mice and their male db/db littermates were randomly grouped (n = 12 per group) and treated with saline (control) or ADI-PEG 20 for
4 weeks.
(A) Schematic of experimental design used to test the metabolic effects of ADI-PEG 20 in db/db mice.
(B) Body weight.
(C) Whole-body fat and lean mass percentage of composition of db/db mice after 5 weeks of ADI-PEG 20 treatment.
(D) Whole-body oxygen consumption (VO2), carbon dioxide (VCO2), and energy expenditure with quantification during light and dark cycles in vehicle- and ADIPEG 20-treated mice.
(E) Body weight to energy expenditure regression test during light cycle.
(F and G) Mitochondrial respiration (F) and OCR parameters of basal respiration, maximal respiration, spare respiration capacity, and ATP-production coupled
respiration (G) of vehicle- and ADI-PEG 20-treated AML12 cells in vitro (n = 12–14 per group).
(H) Serum glucose.
(I and J) Intraperitoneal insulin tolerance test (ITT, I) and glucose tolerance test (GTT, J).
(K) Serum triglyceride, cholesterol, FFA, and LDL-C.
(L) Serum ALT (left), AST (middle), and albumin (right) contents.
(M) Liver triglyceride, cholesterol, and FFA.
(N) Liver sections stained with hematoxylin and eosin (H&E) or oil red O. Scale bars, 100 mm. Liver sections were stained with H&E with steatotic area (e.g.,
aparenchymal space) quantified. Scale bars, 100 mm.
(O) Western blot analysis of FGF21, LC3B, and SQSTM1/p62 in liver samples from db/db AAV8-eGFP and AAV8-arcA mice. b-actin was used as a loading control.
(P) Western blot quantifications of FGF21 (left), LC3B (middle), and SQSTM1/p62 (right) (n = 4 mice per group).
(Q) Serum FGF21.
Data represented in mean ± SEM. Each data point represents an individual animal. Exact p values are shown. Statistical significance was determined using twoway ANOVA in (B), (D), (F), (I), and (J). Unpaired two-tailed Student’s t test was used in (C), (G), (H), (K)–(N), (P), and (Q).
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NEFA by ADI-PEG 20. The therapeutic effect of this agent on intrahepatic cholesterol—but not on TGs or NEFA—was reversed
in ADI-PEG 20-treated FGF21 LKO mice (Figures 4S, 4T, and
4U). Notably, ADI-PEG 20 increased FGF21 peptide, and
FGF21 LKO mice had circulating FGF21 levels that matched
basal FGF21 levels (Figure 4V). Each of these ADI-PEG 20induced changes was associated with reductions in Pck1,
G6pc, and Fbp1, although these reductions were not FGF21
dependent (Figure S3F). Together, the data indicate that hepatocyte FGF21 mediates the thermogenic, insulin/glucose-sensitizing, and anti-dyslipidemic effects of ADI-PEG 20 but is
dispensable for the body mass, composition, and anti-steatotic
effects of FGF21.
Hepatocyte-specific Beclin 1 mediates the antidyslipidemic effect of ADI-PEG 20
Autophagic flux data indicate robust hepatic activation of autophagy in conjunction with FGF21 secretion. We directly tested
the hypothesis that the metabolic actions of ADI-PEG 20 require
hepatocyte-specific autophagic flux through BECN1. To that
extent, we subjected WT (e.g., Becn1fl/fl) and hepatocyte-specific Becn1-deficient mice (BECN1 LKO, e.g., Becn1fl/fl 3 albumin-Cre+) to WD for 12 weeks. This was followed by 4-week
ADI-PEG 20 treatment at 5 IU/week i.p. (Figure 5A). We first
confirmed knockout of BECN1 in liver by gene expression analysis (Figure S4A). ADI-PEG 20 again decreased total body mass
and fat percentage, increased lean mass percentage, and
trended to increase O2-CO2 exchange and caloric expenditure
in both WT and BECN1 LKO mice (Figures 5B–5E) without
changes in respiratory exchange ratios or locomotion (Figures
S4B and S4C). ADI-PEG 20 significantly decreased glucose
and insulin tolerance and fasting insulin in WT mice (Figures
5F–5H). ADI-PEG 20-mediated improvements in glucose tolerance occurred independently of BECN1 (Figure 5F), but
BECN1 deficiency abrogated ADI-PEG 20 effects on insulin
tolerance and fasting insulin levels (Figures 5G and 5H). Similarly,
serum TGs, TC, LDL-C, and NEFA were decreased in drugtreated WT mice, and this effect was attenuated in BECN1
LKO mice (Figures 5I–5L).
Hepatic analysis revealed improved liver TGs, TC, and transaminases AST and ALT in WT but not BECN1 LKO liver (Figures

5M–5P). Similarly, BECN1 was dispensable for ADI-PEG 20induced reductions in liver-weight-to-body-weight ratio (Figures
S4D and S4E). This was not a ubiquitous lipid effect, however, as
hepatic FFA content was suppressed in both ADI-PEG 20treated WT and BECN1 LKO mice (Figure 5Q), independent of
genotype. Hepatic lipid effects were corroborated by histologic
analysis. ADI-PEG 20 reduced steatotic percentage area in WT
but not BECN1 LKO mice (Figure 5R). Surprisingly, BECN1 deficiency reversed ADI-PEG 20 effects on serum and hepatic lipids,
even though serum FGF21 was significantly elevated in ADI-PEG
20-treated BECN1 LKO mice relative to similarly treated WT
mice (Figure 5S). No changes in hepatic stress markers GRP78
or ATF4/CHOP expression were observed (Figure S4F), confirming that the drug was not simply inducing autophagic flux and
FGF21 release due to a somewhat non-specific ER stress
response. Together with FGF21 loss-of-function data, data in
BECN1-deficient mice indicate overall that FGF21 is necessary
but not sufficient to exert the pleiotropic therapeutic actions of
hepatocyte and systemic arginine catabolism.
Systemic autophagy mediates the metabolic effects of
ADI-PEG 20
Arginine is sensed through the SLC38A9-CASTOR1/2 signaling
complexes to activate mTORC1 and block autophagic flux during nutrient-replete conditions.29,30 On that basis, we demonstrated that arginine iminohydrolysis via ADI-PEG 20 and ADI
expression induce hepatic LC3BII accumulation (Figures 2M
and 3N). Yet ADI-PEG 20 retained multiple therapeutic effects
in both WT and BECN1 LKO mice. This prompted the hypothesis
that systemic autophagic flux mediates the breadth of ADI-PEG
20 metabolic action. To directly test the participation of hepatic
and extrahepatic autophagic flux in mediating the effects of ADIPEG 20, we subjected WT and BECN1-haploinsufficient mice to
12 weeks of WD, followed by 4-week vehicle or ADI-PEG 20
treatment (Figure 6A). Again, ADI-PEG 20 reduced body mass
and fat mass and increased percentage lean mass in both WT
and Becn1+/ mice (Figures 6B–6D). In contrast, ADI-PEG 20
increased insulin tolerance and reduced fasting insulin and
glucose (Figures 6E–6G). Reductions in insulin tolerance and
fasting glucose were attenuated in the absence of a haploid
Becn1, although ADI-PEG 20-mediated reductions in fasting

Figure 4. Hepatic-specific Fgf21 knockout partially abolishes ADI-PEG 20-mediated therapeutic effects
(A) Schematic of experimental design used to test the role of ADI-PEG 20 in Fgf21 LKO WD-fed mice.
(B–E) Body weight over time (B), end point body weight (C), and change in body weight (D) of vehicle- and ADI-PEG 20-treated Fgf21 LKO mice (vehicle-treated
Fgf21fl/fl mice, n = 5. ADI-PEG 20-treated Fgf21fl/fl mice, n = 10. ADI-PEG 20-treated Fgf21 LKO mice, n = 7).
(E) Change in body fat and lean composition.
(F) Whole-body oxygen consumption (VO2), carbon dioxide (VCO2), and energy expenditure during light and dark cycle (shaded area) in vehicle- and ADI-PEG 20treated Fgf21 LKO mice.
(G) Body weight to energy expenditure regression test during light and dark cycle.
(H) Serum insulin in vehicle- and ADI-PEG 20-treated Fgf21 LKO mice.
(I and J) Intraperitoneal tolerance tests for glucose (GTT, I) and for glucose (ITT, J).
(K–N) Serum triglyceride (K), cholesterol (L), non-esterified fatty acid (M), and low-density lipoprotein cholesterol (N) in vehicle- and ADI-PEG 20-treated Fgf21
LKO mice.
(O and P) Serum ALT (O) and serum albumin (P) contents.
(Q and R) Liver sections stained with hematoxylin and eosin (H&E, Q) with steatotic area (e.g., aparenchymal space) quantified (R). Scale bars, 100 mm.
(S–U) Triglyceride (S), cholesterol (T), and non-esterified fatty acid (U) contents in the livers of vehicle- and ADI-PEG 20-treated Fgf21 LKO mice.
(V) Serum FGF21 content.
Data represented in mean ± SEM. Each data point represents an individual animal. Exact p values are shown. Statistical significance was determined using twoway ANOVA in (B), (E), (F), (I), and (J). Unpaired two-tailed Student’s t test was used in (C), (D), (H), (K)–(P), and (R)–(V).
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insulin remained BECN1 independent (Figure 6F). ADI-PEG 20
reduced fasting TGs, TC, NEFA, LDL-C, and glucose in WT
mice (Figures 6H–6K). These effects were significantly reversed
in ADI-PEG 20-treated Becn1+/ mice.
In liver, ADI-PEG 20 again reduced hepatic TGs, TC, and
NEFA as well as circulating ALT and AST (Figures 6L–6Q) with
trends toward decreased liver weight and liver-body-weight ratio (Figures S5A and S5B). However, all effects required a full
complement of Becn1, and ADI-PEG 20 failed to reduce any
of these outcomes in Becn1+/ mice. We confirmed this histologically, as ADI-PEG 20 reduced percentage steatotic area in
both WT and Becn1+/ mice, yet ADI-PEG 20-treated Becn1
haploinsufficient mice nevertheless had higher mean percentage steatotic area when compared with drug-treated WT controls (Figure 6R).
Similarly, ADI-PEG 20 broadly increased hepatic amino acid
content and ornithine, urea, and citrulline content. These increases were uniformly muted in ADI-PEG 20-treated Becn1+/
mice (Figure 6S). In contrast, we did not observe consistent
changes in serum amino acid levels (Figure 6T).
arcA and ADI-PEG 20 induced FGF21 and other geneexpression alterations. We thus tested the hypothesis that the
therapeutic effects of ADI-PEG 20 associated with hepatocellular population-specific epigenetic alterations in chromatin
accessibility. We performed single-cell ATAC sequencing in
livers from WT and Becn1+/ mice on a 12-week WD followed
by 4-week ADI-PEG 20 treatment. Of the nine distinct clusters
defined, we differentiated hepatocyte populations from endothelial, Ito, leukocyte, and cholangiocyte cell types based on
key hepatocyte markers. This included albumin, Hnf4a, Hnf1a,
and FoxA1 (Figures 7A–7C). Based on this separation, we noted
that ADI-PEG 20 reduced the inflammatory macrophage population in WT but not in Becn1+/ mice (Figure 7D). Overall,
pseudo-bulk PCA analysis revealed broad separation of accessibility in the chromatin landscape of WT mice treated with
ADI-PEG 20, whereas untreated WT mice clustered indistinguishably with treated and untreated Becn1+/ mice (Figure 7E).
UMAP analysis further demonstrated most prominent separation of hepatocyte chromatin accessibility in WT but not
Becn1+/ mice hepatocytes (Figures 7F and 7G). Chromatin
changes induced by ADI-PEG 20 were thus almost completely
dependent on BECN1, particularly in the hepatocyte population. More detailed comparison of vehicle- and ADI-PEG

20-treated hepatocyte populations demonstrated significant reductions in peaks in encoding regions along chromosome 18
(Figure 7H, Cidea), chromosome 11 (Figure 7I, Fasn), chromosome 19 (Figure 7J, Gpam), chromosome 4 (Figure 7K, Mtor),
and chromosome 11 (Figure 7L, Gpx3). In contrast, increased
chromatin accessibility was demonstrated in ADI-PEG 20treated WT mice along chromosome 1 near the ureagenic
gene Cps1 (Figure 7M). Each of these changes in chromatin
structure was BECN1 dependent. Together, in vivo genetic
data indicate that systemic autophagic flux via BECN1 mediate
the insulin-sensitizing, dyslipidemic, chromatin-restructuring,
and anti-steatotic effects of ADI-PEG 20.
DISCUSSION
Treatments for obesity and its broad sequelae currently fall short
of ideal in their number and breadth of mechanism. Here, we
demonstrate a target process, arginine catabolism, and commandeer a naturally occurring bacterial virulence factor to
leverage this process. Specifically, we show that the high-affinity
arginine deiminase,22 arcA, enhances host arginine catabolism
to activate key hepatocyte fasting-like signals and systemic autophagic flux to ameliorate multiple metabolic complications in
obese mice. We then nominate ADI-PEG 20 to drive these processes exogenously. Finally, we combine in vivo pharmacology,
mouse genetics, and advanced single-cell-based approaches to
delineate an autophagic flux- and FGF21-dependent mechanism that shares common intermediaries with responses generalized fasting, and the canonical hepatocyte glucose fasting
responses.7,17,18,31–34
Arginine ‘‘deprivation’’ generally, and ADI-PEG 20 specifically, have demonstrated utility and safety in clinical35–37
(NCT03922880) and pre-clinical38–42 contexts targeting tumor
metabolism. Indeed, the majority of reports indicate that arginine deprivation attenuates growth in multiple tumor types,43
including among others, breast,41 prostate,44 pancreatic,45
and liver46,47 tumors that specifically lack the rate-limiting
arginine biosynthetic enzyme, argininosuccinate synthetase 1
(ASS1). Yet recent evidence surprisingly suggests that
ASS1 deficiency is common also to livers from patients with
obesity, simple steatosis, and non-alcoholic steatohepatitis.48
Consistent with these findings, experimental NASH models
also exhibit impaired hepatic ureagenesis.49 Therefore, the

Figure 5. Hepatic autophagy is necessary for ADI-PEG 20-mediated therapeutic effects in WD-fed mice
(A) Schematic of experimental design used to test the role of ADI-PEG 20 in WD-fed Becn1 LKO mice.
(B–D) Body weight (B), body fat (C), and lean mass (D) composition in vehicle- and ADI-PEG 20-treated Becn1 LKO mice (n = 9, 10, 5, 5 mice per group).
(E) Whole-body oxygen consumption (VO2), carbon dioxide (VCO2), and energy expenditure during light and dark cycle (shaded area) in vehicle- and ADI-PEG 20treated Becn1 LKO mice.
(F and G) Intraperitoneal tolerance tests for insulin (ITT, F) and for glucose (GTT, G).
(H) Serum insulin in vehicle- and ADI-PEG 20-treated Becn1 LKO mice.
(I–L) Serum triglyceride (I), cholesterol (J), non-esterified fatty acid (K), and low-density lipoprotein cholesterol (L) in vehicle- and ADI-PEG 20-treated Becn1 LKO
mice.
(M) Serum ALT in vehicle- and ADI-PEG 20-treated Becn1 LKO mice.
(N–P) Triglyceride (N), cholesterol (O), and non-esterified fatty acid (P) contents in the livers of vehicle- and ADI-PEG 20-treated Becn1 LKO mice.
(Q and R) Liver sections stained with hematoxylin and eosin (H&E, Q) with steatotic area (e.g., aparenchymal space) quantified (R). Scale bars, 100 mm.
(S) Serum FGF21 content in vehicle- and ADI-PEG 20-treated Becn1 LKO mice.
Data represented in mean ± SEM. Each data point represents an individual animal. Exact p values are shown. Statistical significance was determined using twoway ANOVA in (F) and (G). Unpaired two-tailed Student’s t test was used in (B)–(D), (H)–(P), (R), and (S).
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steatotic and inflamed liver and the hepatic tumor share a degree of arginine dependence to fuel distinct energy-dependent
pathophysiologies. A key difference, however, is that tumors
have high proliferative energy requirements due to increased
pyrimidine biosynthesis, fueled by aspartate shunting in the
absence of ASS1.50 This sensitizes ASS1-deficient tumors to
apoptotic death upon arginine deprivation.42 On the other
hand, the non-proliferative, steatotic hepatocyte exhibits
greater substrate plasticity, which renders it amenable to
non-lethal arginine deprivation. This instead results in hepatocyte-directed adaptations that coordinate hepatic and extrahepatic compensation. This is possible, in large part, because
hepatocytes possess compensatory autophagic and fasting
autocrine and paracrine signaling to rectify nutrient deficiencies cell-autonomously, and direct extrahepatic tissues
to aid in this compensation. For example, we show that hepatocytes secrete FGF21 in response to ADI-PEG 20 treatment,
the overall purpose of which is to enhance peripheral insulin
sensitivity and drive lipid catabolism in response to an
apparent fasting-like state.20,51,52
These concepts of arginine-dependent metabolism may, in
part, explain the exquisite and targeted sensitivity of the steatotic liver to both hepatocyte-directed and systemic arginine
perturbations. This both clinically important and expedient for
at least two reasons. First, these data demonstrate that the
intersection of its arginine sensitivity and the homeostatic plasticity of the liver during arginine deprivation may facilitate the
broad therapeutic effects of ADI-PEG 20. Second, nutrient
sensing functions of the liver permit systemic arginine targeting
with effects that extend those observed in hepatocyte-specific
targeting.
L-arginine is a semi-essential amino acid and is one of the
most versatile amino acids with multiple competing metabolic
fates in the liver. This raises the possibility that long-term
perturbation could negatively impact other aspects of metabolic function. We cannot definitively rule out this possibility.
Although precise time span over which arginine depletion exerts metabolic benefits remains unclear, our prior studies
indicate quite durable 12- to 14-week efficacy of hepatocytespecific Arg2 overexpression in vivo.16 In the current study,
mice were treated with ADI-PEG 20 for up to 5 weeks without
apparent adverse effects. Similarly, two human trials treated
patients with ADI-PEG 20 between 8 and 41 weeks. All of these

patients were evaluated for ADI-PEG 20-treatment-induced
toxicities. Overall, the toxicity was found to be <5%.37 A
more recent clinical study in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies,
24 weeks of arginine depletion was sustained in patients with
no predominant safety signal observed other than hematologic
toxicity. All cases were resolved and manageable.53 Moreover,
human studies indicate rapid and persistent arginine depletion
up to 18 weeks after initial dosing,54 and an ongoing phase 3
trial will define ADI-PEG 20 durability through up to 103 weeks
after initial dosing (NCT03449901). The current evidence does
not suggest obvious deleterious metabolic effects of chronic
arginine deprivation. Similarly, data on effects of long-term
L-arginine supplementation are conflicting in both pre-clinical
and clinical studies,23,55–58 Taken together, the data do not
reveal negative metabolic sequelae from chronic modulation
of nitrogen status. What is clear is the net metabolic benefit
at least of short-term arginine manipulation. Nevertheless, we
anticipate that the hepatocyte epigenomic alterations we
observed in association with the metabolic effects of ADIPEG 20 extend the effective durability of arginine depletion
beyond dosing of the drug. The precedent for this phenomenon
is the well-known epigenetic and durable effects of IF and CR
on host metabolism.59–61 Yet independent of its durability, the
clinical utility of even short-term arginine-targeting therapy remains. Here, we directly modeled arcA efficacy in a leptin-melanocortin pathway signaling-deficient db/db diabetic model.62
This by itself may address an unmet need that exists in treating
monogenic and other refractory obesity, wherein acute weight
loss preceding bariatric surgery optimizes surgical outcomes.
This currently represents one unique challenge that even
short-term metabolic therapy could address.
A second potential limitation of this approach is that ADIPEG 20 does not clearly invoke a single, linear cascade to produce its effects. It appears that cell-autonomous autophagic,
epigenetic, and autocrine/endocrine effects of this therapy
are all contributory to its effect, akin to a broad stimulus,
such as fasting, caloric restriction, or carbohydrate restriction.
Furthermore, current data demonstrate that BECN1, a canonical autophagic mediator protein, may have pleiotropic functions that go beyond autophagic flux. This includes functions
such as vesicular sorting, autophagy-dependent cell death,
centrosome functions, cytokinesis, and vision cycle.63–65 On

Figure 6. Whole-body Becn1 Het abolishes the therapeutic effects of ADI-PEG 20 in WD-fed mice
(A) Schematic of experimental design used to test the role of ADI-PEG 20 in Becn1Het WD-fed mice.
(B–D) Body weight (B), body fat (C), and lean mass (D) percentage of composition of vehicle- and ADI-PEG 20-treated Becn1 Het mice (n = 7, 3, 7, and 9 mice per
group).
(E) Intraperitoneal tolerance tests for insulin (ITT).
(F and G) Serum insulin (F) and serum glucose (G) in vehicle- and ADI-PEG 20-treated Becn1Het mice.
(H–K) Serum non-esterified fatty acid (H), low-density lipoprotein cholesterol (I), triglyceride (J), and cholesterol (K) in vehicle- and ADI-PEG 20-treated Becn1 Het
mice.
(L and M) Serum ALT (L) and serum albumin (M) contents in vehicle- and ADI-PEG 20-treated Becn1 Het mice.
(N–P) Triglyceride (N), cholesterol (O), and non-esterified fatty acid (P) contents in the livers of vehicle- and ADI-PEG 20-treated Becn1 Het mice.
(Q and R) Liver sections stained with hematoxylin and eosin (H&E, Q) with steatotic (e.g., aparenchymal space) quantified (R). Scale bars, 100 mm.
(S and T) Targeted metabolomic analysis of liver (S) and serum (T) amino acids and urea cycle intermediaries from vehicle- and ADI-PEG 20-treated Becn1Het
mice.
Data represented in mean ± SEM. Each data point represents an individual animal. Exact p values are shown. Statistical significance was determined using twoway ANOVA in (E). Unpaired two-tailed Student’s t test was used in (B)–(D) and (F)–(R).
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this basis, we acknowledge the potentially much broader
functions of BECN1 that may indicate as yet unidentified processes mediating the therapeutic effects of forced arginine
catabolism.
In contrast, more targeted therapies, such as melanocortin receptor agonists, act on a cognate receptor with well-defined action.62,66 Regardless of mechanism, however, this pleiotropism
may ultimately prove to be a primary strength on two bases.
First, it is likely that most obesity is a common final manifestation
of multiple signaling, carbon flux, and autophagic defects that
culminate in a common, gross phenotype. Second, perturbations in linear pathways, at least historically using leptin as the
exemplar, have proved to permit homeostatic compensation to
attenuate these therapeutic effects.67 We postulate that adaptation to the broader perturbation of arginine deprivation may
attenuate the degree to which compensatory mechanisms can
attenuate its therapeutic effects. And whereas we do not yet
directly demonstrate the connection between arginine turnover
and the requirement for fasting-like signals (FGF21, autophagic
flux) in the ADI-PEG 20 response, we hope to highlight in this
work the concept of arginine deprivation as a tractable therapeutic pathway that mediates its effects through canonical fastinglike response pathways.
Thus, overall, we have demonstrated that systemic and hepatocyte-directed arginine deprivation is sufficient to induce adaptive hepatocyte fasting-like responses, and we introduce a
readily available pharmacotherapy that leverages this pathway.
The data justify arginine catabolism as a target pathway in treating metabolic disease, and in light of precedent safety and efficacy data in patients over the course of a decade in clinical
use, the data justify the use of ADI-PEG 20 therapy to drive therapeutic arginine catabolism in human clinical trials against
obesity and its metabolic sequelae.
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Figure 7. Single-cell ATAC sequencing reveals alterations in the hepatocyte-selective chromatin accessibility landscape upon systemic
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(A) UMAP projection of 40773 liver cells from scATAC-seq where cells that share similar chromatin accessibility landscape are grouped through unsupervised
clustering. Each point represents a single cell captured.
(B) Dot-plot analysis of known cell-specific marker gene expression used to assign identity to the clusters.
(C) UMAP visualization of the clusters showing the assigned identity for each cell type identified.
(D) The proportion of cells that contributes to each cell type by each liver sample.
(E) Psuedobulk principle component analysis of all scATAC-seq samples. The first two principal components (PCs) are plotted. Variance proportions are shown
along each component axis. The plot model 77% of the total data variance.
(F) UMAP visualization of cell clusters split by genotype between wild-type (WT) and Becn1+/ (Becn1Het).
(G) UMAP visualization of cell clusters split by treatment of vehicle and ADI-PEG 20 between genotypes.
(H–M) Hepatocyte-specific chromatin landscapes are shown for genes Cidea (H), Fasn (I), Gpam (J), Mtor (K), Gpx3 (I), and Cps1 (M).
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Jackson Laboratory

RRID: IMSR_JAX:000664
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Jackson Laboratory
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Jackson Laboratory
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Jackson Laboratory
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GraphPad Software Inc.
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Materials availability
This study did not generate new unique reagents.
Data and code availability
d

d
d

Bulk RNA-seq data and single-cell ATAC-seq data have been deposited at the Gene Expression Omnibus (GEO) with accession codes GSE191295 and GSE192413, respectively, and are publicly available as of the date of publication. Accession
numbers are also listed in the key resources table.
This paper does not generate custom code.
Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon
request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice, diets, and treatments
All animal protocols were approved by the Washington University School of Medicine Animal Studies Committee. Male C57B/6J
mice, db/db mice, Becn1 heterozygous (Becn1+/) mice, Becn1fl/fl mice, and Fgf21fl/fl mice (mouse strains 000664, 000642,
018429, 028794, and 022361 respectively) were purchased directly from the Jackson Laboratory (Bar Harbor, ME). Liver specific
knockout mice of Becn1/ and Fgf21/ were generated from Becn1fl/fl mice and Fgf21fl/fl mice which were bred with Alb1-Cre
transgenic mice from Jackson Laboratory (mouse strain 016832).
All strains of genetically altered mice were on a C57BL/6J background. Control mice were negative for Cre recombinase and
matched by genetic background, age, and sex. All animals were housed at the Washington University Medical School in St. Louis
in a 12-h alternating light-dark, temperature-controlled, specific pathogen-free barrier facility prior to and throughout experimentation.
All animals received humane care and procedures were performed in accordance with the approved guidelines by the Animal
Studies Committee at Washington University School of Medicine. All animal studies were performed in accordance with the criteria
and ethical regulations outlined by the Institutional Animal Care and Use Committee (IACUC).
Five-week-old mice were fed ad libitum: a normal chow diet (NCD) or a Western diet (WD) (TD.88137: 42% kcal fat; Envigo Teklad
Diets, Madison, WI, USA) for 16 weeks. All animals received non-supplemented drinking water.
For ADI-PEG 20 studies, five-week-old male mice were fed a normal chow diet (NCD) or a Western diet (TD.88137, Envigo Teklad
Diets, Madison, WI, USA) for 12 weeks prior to treatment and then ADI-PEG 20 (Polaris Pharmaceuticals, Inc., San Francisco, CA,
USA) treatment started for 4 weeks while continuously on the same diet. Once per week, 5IU/mouse of ADI-PEG 20 was administered
through intraperitoneal injection. At the end of the experiment, animals were sacrificed, and the liver, fat and serum were harvested for
subsequent analysis.
Cell cultures and treatment
a mouse liver 12 (AML12) cells were purchased from American Type Culture Collection (ATCC) [CRL-2254; Research Resource Identifier (RRID): CVCL_0140] and maintained per American Type Culture Collection guidelines. AML12 cells were cultured in Dulbecco’s
Modified Eagle Medium high glucose/Ham’s F12 (DMEM-F12 (1:1) (1X), GIBCO) and supplemented with 10% fetal bovine serum
(FBS, GIBCO), 40 ng/mL dexamethasone (Sigma Aldrich), 10 mg/mL insulin, 5.5 mg/mL transferrin, and 5 ng/mL selenium (GIBCO),
and 1% penicillin/streptomycin/fungizone (GIBCO). AML12 cells were propagated in tissue culture treated 10 cm dishes (TPP). All cell
lines were seeded at > 95% viability.
METHOD DETAILS
AAV8- and adenovirus-mediated overexpression
Serotype 8 AAV (AAV8) was administered via tail vein as we previously reported.16 The arcA viral vectors (AAV8-TBG-arcA and AdarcA) were obtained directly from Vector Biolabs Inc (Malvern, PA, USA).
Intraperitoneal glucose tolerance test
Intraperitoneal glucose tolerance tests were carried out on mice fasted for 6 hours on aspen bedding. Basal blood glucose concentrations were determined for each mouse prior to glucose administration using a hand-held glucose meter (Arkray USA, Inc., Minneapolis, MN, USA). Each mouse then received 2g per kg body weight of glucose, except for db/db mice, which received 1 g per kg
body weight of glucose through intraperitoneal injection and blood glucose concentrations were subsequently measured at 30, 60,
90 and 120 minutes post glucose administration.
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Intraperitoneal insulin tolerance test
Intraperitoneal insulin tolerance tests were carried out on mice fasted for 4 hours on aspen bedding. Basal blood glucose concentrations were determined for each mouse prior to insulin administration using a hand-held glucose meter (Arkray USA, Inc., Minneapolis,
MN, USA). Each mouse then received 0.75 IU per kg body weight of insulin (Lilly USA, LLC Indianapolis, IN, USA) through intraperitoneal injection and blood glucose concentrations were subsequently measured at 30, 60, 90 and 120 minutes post insulin
administration.
Clinical chemistry measurements and hepatic lipid analyses
For all other serum analyses, submandibular blood collection was performed immediately prior to sacrifice and serum was separated.
Insulin ELISA (Millipore #EZRMI-13K), triglycerides (Thermo Fisher Scientific #TR22421), cholesterol (Thermo Fisher Scientific
#TR13421), and free fatty acids (Wako Diagnostics #999-34691, #995-34791, #991-34891, #993-35191) quantification were performed using commercially available reagents according to manufacturer’s directions. Albumin levels were quantified using an
AMS LIASYS Chemistry Analyzer.
Measurement of liver triglycerides
Liver-specific lipids were extracted and analyzed from snap frozen liver tissue samples. 50 mg hepatic tissue samples were homogenized in 2:1 chloroform:methanol. In total, 0.25%–0.5% of each extract was evaporated overnight prior to biochemical quantification of
triglycerides, cholesterol, and free fatty acids (FFA) using reagents described above, precisely according to manufacturer’s directions.
Body composition analysis
Body composition analysis was carried out in unanesthetized mice using an EchoMRI 3-1 device (Echo Medical Systems) via the
Washington University Diabetic Mouse Models Phenotyping Core Facility.
Indirect calorimetry and food intake measurement
All measurements were performed in a PhenoMaster System (TSE systems) via the Washington University Diabetic Mouse Models Phenotyping Core Facility, which allowed metabolic performance measurement and activity monitoring by an infrared light = beam frame.
Mice were placed at room temperature (22–24  C) in separate chambers of the PhenoMaster open-circuit calorimetry. Mice were allowed
to acclimatize in the chambers for 4 h. Food and water were provided ad libitum in the appropriate devices. The parameters of indirect
calorimetry (VO2, VCO2, respiratory exchange ratio (RER), heat and movement) were measured for at least 24 h for a minimum of one light
cycle (6:01 am to 6:00 pm) and one dark cycle (6:01 pm to 6:00 am). Presented data are average values obtained in these recordings.
Quantitative real-time RT-PCR
Total RNA was prepared by homogenizing snap-frozen livers or cultured hepatocytes in Trizol reagent (Invitrogen #15596026) according to the manufacturer’s protocol. cDNA was prepared using QIAGEN Quantitect reverse transcriptase kit (QIAGEN
#205310). Real-time qPCR was performed with Step-One Plus Real-Time PCR System (Applied Biosystems) using SYBR Green
master Mix Reagent (Applied Biosystems) and specific primer pairs. Relative gene expression was calculated by a comparative
method using values normalized to the expression of an internal control gene.
Immunoblotting
Tissues were homogenized in RIPA lysis buffer (50mM Tris, 1% NP-40, 0.1% SDS, 0.5% Sodium Deoxycholate, 150 mM NaCl, pH
8.0) supplemented with protease and phosphatase inhibitors (Thermo Scientific). After homogenization, lysate was centrifuged at
18,000 g for 15 min at 4C, and the supernatant was recovered. Protein concentration was determined by BCA Assay Kit (Thermo
Scientific) and was adjusted to 2mg/mL. Samples for western blotting were prepared by adding Laemmli buffer at a ratio of 1:1
and heating at 95 C for 5 min. The prepared samples were subjected to 10% or 13% SDS-PAGE, followed by electrical transfer
onto a nitrocellulose membrane using the Trans-Blot Turbo system (Bio-Rad). After blocking the membrane with 5% milk in
TBST, the membrane was incubated in primary antibody at 4 C overnight. The blot was developed after secondary antibody incubation using Pierce ECL Western Blotting Substrate (Thermo Scientific). Blots were developed according to the manufacturer’s instructions. Protein expression levels were quantified with ImageJ Lab software and normalized to the levels of b-Actin.
Antibodies
Antibodies against FGF21 (Abcam Cat. # ab171941), SQSTM1/p62 (Abcam Cat. # ab56416), LC3B (Novus Biologicals Cat. # NB1002220), and b-Actin (Cell Signaling Cat. # 3700S). The dilution ratio for all primary antibodies was 1:1,000. The secondary antibodies
used in this study were peroxidase-conjugated anti-rabbit IgG (Cell Signaling Cat. # 7074S) and anti-mouse IgG (Cell Signaling Cat. #
7076S) were purchased from Cell Signaling Technology (CST) (Beverly, MA, USA), in which were used at a 1:5,000 dilution.
Histological analysis
Formalin-fixed paraffin-embedded liver sections were stained by H&E via the Washington University Digestive Diseases Research
Core Center. OCT-embedded frozen liver sections were stained by Oil Red O according to standard protocols flowered by micro-
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scopic examination. Three liver sections were examined and evaluated for each animal. For Oil red-O staining, ice-cold methanolfixed frozen sections from mice were stained according to described protocols.11,12,68
RNA-seq
RNA-seq was performed by the Washington University Genome Technology Access Center (GTAC). Library preparation was performed with 10uG of total RNA with a Bioanalyzer RIN score greater than 8.0. Ribosomal RNA was removed by poly-A selection using
Oligo-dT beads (mRNA Direct kit, Life Technologies). mRNA was then fragmented in buffer containing 40mM Tris Acetate pH 8.2,
100mM Potassium Acetate and 30mM Magnesium Acetate and heating to 94 degrees for 150 s. mRNA was reverse transcribed
to yield cNDA using SuperScript III RT enzyme (Life Technologies, per manufacturer’s instructions) and random hexamers. A second
strand reaction was performed to yield ds-cDNA. cDNA was blunt ended, had an A base added to the 30 ends, and then had Illumina
sequencing adapters ligated to the ends. Ligated fragments were then amplified for 12 cycles using primers incorporating unique
index tags. Fragments were sequenced on an Illumina HiSeq-3000 using single reads extending 50 bases.
RNA-seq reads were aligned to the Ensembl release 76 top-level assembly with STAR version 2.0.4b. Gene counts were derived
from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5. Transcript counts were produced
by Sailfish version 0.6.3. Sequencing performance was assessed for total number of aligned reads, total number of uniquely aligned
reads, genes and transcripts detected, ribosomal fraction known junction saturation and read distribution over known gene models
with RSeQC version 2.3.
To enhance the biological interpretation of the large set of transcripts, grouping of genes/transcripts based on functional similarity
was achieved using the R/Bioconductor packages GAGE and Pathview. GAGE and Pathview were also used to generate pathway
maps on known signaling and metabolism pathways curated by KEGG.
SC-ATAC sequencing
Tissues were harvested and frozen samples were sent to Active Motif to perform the scATAC-seq assay. Tissues were prepared as
described by 10X Genomics Demonstrated Protocol – Nuclei Isolation from Mouse Brain Tissue for Single Cell ATAC Sequencing Rev
B with some modifications. Briefly, tissues were minced in ice cold lysis buffer followed by dounce homogenization and incubated on
ice for 10 minutes. Lysate was strained, washed, and nuclei were resuspended and counted using a Countess II FL Automated Cell
Counter. Isolated nuclei were then used as input following the 10X Genomics Chromium Next GEM Single Cell ATAC Reagent Kits
v1.1 manual. Targeting a 5,000 nuclei recovery, samples were added to the tagmentation reaction, loaded into the Chromium
Controller for nuclei barcoding, and prepared for library construction following manufacturer’s protocol (10X Genomics PN1000175). Resulting libraries were quantified using the KAPA Library Quantification Kit for Illumina platforms (KAPA Biosystems),
and sequenced with PE34 sequencing on the NextSeq 500/550 sequencer (Illumina).
Sequenced data were processed with the Cell Ranger ATAC software, with alignment to the mouse (mm10) genome. The Cell
Ranger output files were used as input to Active Motif’s proprietary analysis program, which creates Excel tables containing detailed
information on cluster-specific peak locations, gene annotations, and motif enrichment.
The alignment files generated by Cell Ranger were also processed as pseudo-bulk ATAC-Seq samples. Duplicate reads were
removed, only reads mapping as matched pairs and only uniquely mapped reads (mapping quality R 1) were used for further analysis.
Alignments were extended in silico at their 30 ends to a length of 200 bp and assigned to 32-nt bins along the genome. The resulting
histograms (genomic ‘‘signal maps’’) were stored in bigWig files. Peaks were identified using the MACS 2.1.0 algorithm at a cutoff of p
value 107, without control file, and with the –nomodel option. Peaks that were on the ENCODE blacklist of known false ChIP-Seq
peaks were removed. Signal maps and peak locations were used as input data to Active Motif’s proprietary analysis program, which
creates Excel tables containing detailed information on sample comparison, peak metrics, peak locations, and gene annotations.
Targeted metabolomics
We performed targeted metabolomics as reported with minor modifications.69 Briefly, the liver samples were homogenized in water
(4 mL/g liver). The amino acids in 20 mL of mouse serum or liver homogenate were extracted with protein precipitation in the presence
of internal standards (13C6,15N-Ile, d3-Leu, d8-Lys, d8-Phe, d8-Trp, d4-Tyr, d8-Val, d7-Pro, 13C4-Thr, d3-Met, d2-Gly, 15N2-Asn,
d4-Cit, d3-Asp, 13C5-Gln, 13C6-His, d3-Glu, d4-Ala, d3-Ser, 13C5-Orn, and 13C6-Arg). Quality control (QC) samples for livers and
sera were prepared from pooled partial study samples and injected every 5 study samples to monitor intra-batch precision. Only the
lipid species with CV% < 15% for QC injections are reported. The Ile, Leu, Lys, Phe, Trp, Tyr, Val, Pro, Thr, Met, Gly, Asn, Cit, Asp, Gln,
His, Glu, Ala, Ser, Orn, and Arg were analyzed on 4000 QTRAP mass spectrometer coupled with a Prominence LC-20AD HPLC system. Data processing was conducted with Analyst 1.5.1 (Applied Biosystems).
Extracellular flux analysis
In vitro respiration measurements were performed using the Seahorse xFE96 Analyzer (Agilent) with the AML12 immortalized mouse
hepatocyte cell line. Cells were seeded to near confluency. Cells were treated with adenoviruses, Ad-eGFP (Control) or Ad-arcA, for
24 hours in regular media, and subjected to fresh media for an additional 24 hours prior to analysis. The Seahorse Mito Stress Test kit
(Agilent) was used according to manufacturer instructions.
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QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
Data were analyzed using GraphPad Prism version 7.05 (RRID:SCR_015807). p < 0.05 was defined as statistically significant. Data
shown are as mean ± SEM. Unpaired 2-tailed homoscedastic t tests with Bonferroni post hoc correction for multiple comparisons
were used for all analyses unless otherwise noted in the Figure Legends. Two-way ANOVA was also used for analyses with two independent variables.
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Figure S1. The effect of hepatocyte-specific arcA expression in db/db mice. Related to Figures 1 and 2.
(A) mRNA expression of arcA in the livers of AAV8-eGFP or AAV8-arcA injected db/db mice by qPCR. Gene expression was normalized
to  -actin mRNA levels. Liver weights.
(B and C) Respiration exchange ratio (RER, B) and locomotion (C) during light and dark cycle (shaded area) in AAV8-eGFP or AAV8arcA injected db/db mice.
(D) Food consumption measured in AAV8-eGFP or AAV8-arcA injected db/db mice.
(E and F) Liver weights (E) and liver weight/body weight ratio (F) of AAV8-eGFP or AAV8-arcA injected db/db mice.
(G) Hepatic mRNA expression of fatty acid transports by qPCR.
(H) Gene ontology terms for significant pathways related to DNL and fatty acid oxidation.
(I) Hepatic mRNA expression of cytokines and chemokines by qPCR.
(J) Hepatic mRNA expression of macrophage infiltration by qPCR.
(K) Hepatic mRNA expression of fibrosis development by qPCR.
(L) Hepatic mRNA expression of urea cycle enzymes by qPCR.
(M) Hepatic mRNA expression of glutamine synthetase (Glul) by qPCR.
Data represented in mean ± s.e.m. Each data point represents an individual animal. Exact P-value are shown. Statistical significance was
determined using unpaired two-tailed Student’s t-test. Gene expression was normalized to  -actin mRNA levels.
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Figure S2. The effect of ADI-PEG 20 treatment in db/db mice. Related to Figure 3.
(A) Hepatic mRNA expression of Ghrelin (Ghrl) and Leptin (Lep) by qPCR.
(B) Western blot analysis of GHRL protein abundance in ADI-PEG 20-treated db/db mice.
(C) Food consumption measured in vehicle and ADI-PEG 20 treated db/db mice.
(D) Body weight changes superimposed with daily food consumption in vehicle and ADI-PEG 20 treated db/db mice.
(E and F) Respiration exchange ratio (RER, C) and locomotion (D) during light and dark cycle (shaded area) in vehicle and ADI-PEG 20
treated db/db mice.
(G and H) Liver, white adipose tissue , and brown adipose tissue (iBAT) weights (E). Liver, white, and brown adipose tissue weight/body
weight ratio (F) of vehicle and ADI-PEG 20 treated db/db mice.
(I) Hepatic mRNA expression of cytokines and chemokines by qPCR.
(J) Hepatic mRNA expression of macrophage infiltration related genes by qPCR.
(K) Hepatic mRNA expression of fibrosis development related genes by qPCR.
(L) Hepatic mRNA expression of urea cycle enzymes by qPCR.
(M) Hepatic mRNA expression of glutamine synthetase (Glul) by qPCR.
(N) Hepatic mRNA expression of thermogenic genes, Pgc-1α, Fgf21, and Ucp1 by qPCR.
(O) Hepatic mRNA expression of p62/Sqstm1 expression by qPCR.
(P) Western blot analysis of mTORC1 signaling substrates in liver samples from vehicle and ADI-PEG20 treated db/db mice. -Actin was
used as a loading control.
(Q) Western blot quantifications of (P).
(R) Hepatic mRNA expression of genes related to fatty acid β-oxidation by qPCR.
(S) Hepatic mRNA expression of gluconeogenic genes by qPCR.
(T) Hepatic mRNA expression of genes related in fatty acid intake and export qPCR.
(U) mRNA expression of Grp78 and Atf4 in the livers of db/db mice treated with or without ADI-PEG 20 by qPCR. Gene expression was
normalized to  -actin mRNA levels.
Data represented in mean ± s.e.m. Each data point represents an individual animal. Exact P-value are shown. Statistical significance was
determined using unpaired two-tailed Student’s t-test. Gene expression was normalized to  -actin mRNA levels.
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Figure S3. Supplemental information on ADI-PEG 20-treated Fgf21fl/fl and Fgf21-/- LKO mice. Related to Figure 4.
(A) Food consumption measured in vehicle and ADI-PEG 20 treated Fgf21 LKO mice.
(B and C) Respiration exchange ratio (RER, C) and locomotion (D) during light and dark cycle (shaded area) in vehicle and ADI-PEG 20
treated Fgf21 LKO mice.
(D and E) Liver weights (D). Liver weight/body weight ratio (E) of vehicle and ADI-PEG 20 treated Fgf21 LKO mice.
(F) Hepatic mRNA expression of gluconeogenic genes, Pck1, G6pc, and Fbp1 by qPCR. Gene expression was normalized to  -actin
mRNA levels.
Data represented in mean ± s.e.m. Each data point represents an individual animal. Exact P-value are shown. Statistical significance was
determined using unpaired two-tailed Student’s t-test.
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Figure S4. Supplemental information on ADI-PEG 20-treated Becn1fl/fl and Becn1-/- LKO mice. Related to Figure 5.
(A) mRNA expression of Becn1 in the livers of Becn1 LKO mice treated with or without ADI-PEG 20 by qPCR. Gene expression was
normalized to  -actin mRNA levels.
(B and C) Respiration exchange ratio (RER, C) and locomotion (D) during light and dark cycle (shaded area) in vehicle and ADI-PEG 20
treated Becn1 LKO mice.
(D and E) Liver weights (D). Liver weight/body weight ratio (E) of vehicle and ADI-PEG 20 treated Becn1 LKO mice.
(F) mRNA expression of Grp78 and Atf4 in the livers of Becn1 LKO mice treated with or without ADI-PEG 20 by qPCR. Gene expression
was normalized to  -actin mRNA levels.
Data represented in mean ± s.e.m. Each data point represents an individual animal. Exact P-value are shown. Statistical significance was
determined using unpaired two-tailed Student’s t-test.
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Figure S5. Supplemental information on ADI-PEG 20-treated Becn1+/+ and Becn1+/- mice. Related to Figure 6.
(A) Liver weights.
(B) Liver weight/body weight ratio of vehicle and ADI-PEG 20 treated BecnHet mice.
Data represented in mean ± s.e.m. Each data point represents an individual animal. Exact P-value are shown. Statistical significance was
determined using unpaired two-tailed Student’s t-test.

Table S1.

Gene
β-Actin
arcA
Arg1
Asl
Ass1
Atf4
Becn1
Ccl2
Cd36
Cd68
Col1α1
Cps1
Cpt-1α
Cpt-1β
Cxcl9
Fbp1
Fgf21
G6pc
Gck
Ghrl
Glul
Grp78
Il-1β
Il-6
Lep
Mmp2
Mttp
Otc
p62/Sqstm1
Pck1
Pgc1α
Slc25a15
Timp1
Tnfα
Ucp1
Ucp2
Ucp3

Forward (5' - 3')
GAT TAC TGC TCT
ATT CAC CCA TCG
CTC CAA GCC AAA
CTA TGA CCG GCA
ACA CCT CCT GCA
AGC AAA ACA AGA
ATG GAG GGG TCT
TTA AAA ACC TGG
GGA ACT GTG GGC
TGT CTG ATC TTG
GCT CCT CTT AGG
ACA TGG TGA CCA
AGT GGC CTC ACA
GCA CAC CAG CAG
GGA GTT CGA GGA
CAC CGC GAT CAA
CTG CTG GGG GTC
TCT GTC CCG GAT
CAA CTG GAC CAA
TCA AGC TGT CAG
TGA ACA AAG GCA
GAA AGG ATG GTT
GCA ACT GTT CCT
CTG CAA GAG ACT
GAG ACC CCT GTG
CAA GTT CCC CGG
ATG ATC CTC TTG
ACA CTG TTT GCC
AGG ATG GGG ACT
GAT GGG CAT ATC
ACA CCG CAA TTC
GCT GCC TCA AGA
GCA ACT CGG ACC
CAG GCG GTG CCT
AGG CTT CCA GTA
ATG GTT GGT TTC
CTG CAC CGC CAG

GGC
CAA
GTC
TCT
TCC
CAG
AAG
ATC
TCA
CTA
GGC
AGA
GAC
GCA
ACC
AGC
TAC
CTA
GGG
GAG
TCA
AAT
GAA
TCC
TCG
CGA
GCA
TAG
TGG
TGT
TCC
CCT
TGG
ATG
CCA
AAG
ATG

TCC
ACG
CTT
GTG
TCG
CAG
GCG
GGA
TTG
GGA
CAC
TTC
TCC
GTA
CTA
CAT
CAA
CCT
CTT
CTC
AGC
GAT
CTC
ATC
GTT
TGT
GTG
AAA
TTG
GCT
CTT
ACT
TCA
TCT
TTA
GCC
AGT

TAG
AC
AGA
GAA
T
CC
TC
ACC
C
CCG
T
CTC
AG
GCT
GTG
CT
G
TG
CAA
AGT
AAA
GCT
AAC
CAG
C
C
CTT
GCC
C
GG
GT
CC
TAA
C
GGT
ACA
TT

G

AA

G
TT

A
TG
GAG
T

Reverse (5' - 3')
GAC TCA TCG TAC
GCG ATT TCC ATC
AGG AGC TGT CAT
AGC AAC CTT GTC
GCT CAC ATC CTC
ACT CTC TTC TTC
TGG GCT GTG GTA
GCA TTA GCT TCA
CAT GAG AAT GCC
GAG AGT AAC GGC
CCA CGT CTC ACC
TTC CTC AAA GGT
GCC CAT GTT GTA
CAG GAG TTG ATT
GGG ATT TGT AGT
AGG TAG CGT AGG
CTG CGC CTA CCA
GCT GGC AAA GGG
TGT GGC CAC CGT
TTG TCA GCT GGC
CAG TCC AGG GTA
GTC TTC AAT GTC
ATC TTT TGG GGT
AGT GGT ATA GAC
CTG CGT GTG TGA
TTC TGG TCA AGG
TGA GAG GCC AGT
CCA TGA CAG CCA
TCA CAG ATC ACA
CAG CCA CCC TTC
CGG CGC TCT TCA
CCG TAA CAC ATG
CGG CCC GTG ATG
CGA TCA CCC CGA
CTG AGT GAG GCA
CGG TAT CCA GAG
ATC ATG GCT TGA

TCC
TCG
TAG
CAA
AAT
CCC
AGT
GAT
TCC
CTT
ATT
GCG
CAG
CCA
GGA
ACG
CTG
TGT
GTC
GCC
CGG
CGC
CCG
AGG
AAT
TCA
TGT
TGA
TTG
CTC
ATT
AAC
AGA
AGT
AAG
GGA
AAT

TGC
GTA
GGA
CCC
GAA
CTT
AAT
TTA
AAA
TTT
GGG
ACC
CTT
GAC
TCG
ACT
TTC
AGT
ATT
TCT
GTC
ATC
TCA
TCT
GTC
CCT
GTG
TTG
GGG
CTT
GCT
AGC
AAC
TCA
CTG
AAG
CGG

Table S1. Mouse primer sequences used for quantitative RT-PCR. Related to STAR Methods.

TTG
GCT
CAT
TTG
CAC
GC
GGA
CGG
CAC
GTG
G
AAT
CC
AGG
TGC
TCA
C
GT
C
T
TT
CTG
ACT
GTT
ATT
GTC
AC
TCC
TGC
AG
TT
ACC
T
GTA
ATT
TGA
ACC

C
CT
GT
A

TA

GG
G
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